

5. <http://www.mhlw.go.jp/shingi/2007/04/dl/s0426-6g.pdf>.
6. <http://www.jpec.or.jp/contents/c01/link.html>.
7. http://ganjoho.ncc.go.jp/pro/med_info/drug/index.html.
8. <http://ganjoho.ncc.go.jp/pro/statistics/statistics.html>.
9. Nagpal M, Nagpal K, Nagpal PN. A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). *Indian J Ophthalmol*. 2007;55(6):437-9.
10. Saif MW, Kang SP, Chu E. Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies. *Oncology (Williston Park)*. 2006;20(14 Suppl 10):11-9.
11. Flaherty KT. Sorafenib: delivering a targeted drug to the right targets. *Expert Rev Anticancer Ther*. 2007;7(5):617-26.
12. Felip E, Santaripa M, Rosell R. Emerging drugs for non-small-cell lung cancer. *Expert Opin Emerg Drugs*. 2007;12(3):449-60.
13. DeVita VT Jr, Hellman S, Rosenberg SA, editors. *Cancer, principles and practice of oncology*. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 296-7.
14. Notification No.725 of Yakuhatu, Ministry of Welfare dated 25 August, 1993.
15. Notification No.0227016 of Yakushokushinsahatsu, Ministry of Health Labour and Welfare dated 27 February, 2004.
16. Report on anticancer drug combination regimen. http://www.infopmd.go.jp/kyoten/gan_heiyou_index.html.
17. Vickers AJ, Kuo J, Cassileth BR. Unconventional anticancer agents: a systematic review of clinical trials. *J Clin Oncol*. 2006;24(1):136-40.
18. Fujiwara Y, Kobayashi K. Oncology drug clinical development and approval in Japan: the role of the pharmaceuticals and medical devices evaluation center (PMDEC). *Crit Rev Oncol Hematol*. 2002;42(2):145-55.
19. Kocs D, Fendrick AM. Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience. *Am J Manag Care*. 2003;9(5):393-400; quiz 401-2.